Pfizer
Prescribe Paxlovid, but Know the Risks
Paxlovid reduces hospitalizations and deaths from COVID-19, so clinicians should not avoid prescribing it for mild ...
JUNE 8, 2022
Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts
Pfizer announced that it is introducing three new biosimilars, ZIRABEV (bevacizumab-bvzr), RUXIENCE ...
FEBRUARY 14, 2020
FDA Approves Pfizer Biosimilar to Rituxan
The FDA approved rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab (Rituxan, Genentech), for several ...
JULY 25, 2019
FDA Approves Bavencio With Inlyta for Patients With Advanced Renal Cell Cancer
Bavencio with Inlyta is the first FDA approval for an anti–PD-L1 therapy as part of a combination regimen for ...
MAY 16, 2019
Trazimera, Biosimilar to Herceptin, Gains Approval
A new biosimilar was approved for Herceptin to treat HER2-overexpressing breast cancer and HER2-overexpressing ...
MARCH 12, 2019
FDA Approves Talzenna for gBRCAm HER2– Breast Ca
The FDA approved Talzenna, a poly(adenosine diphosphate–ribose) polymerase inhibitor, for patients with ...
OCTOBER 18, 2018
FDA Warns of Higher Risk for Ca Relapse With Long-Term Azithromycin in Allo-HCT Pts
Results of a clinical study, which attempted to prevent this serious lung condition with azithromycin prophylaxis, ...
AUGUST 10, 2018
FDA Approves Nivestym, Second Biosimilar of Neupogen
The FDA approved Pfizer's Nivestym, a biosimilar of Neupogen for all eligible indications as the reference ...
JULY 25, 2018
First Epoetin alfa Biosimilar Receives FDA Approval for Anemia
Retacrit is the first U.S. biosimilar erythropoiesis-stimulating agent. Although not listed as an interchangeable ...
MAY 21, 2018
New Indication Granted for Bosutinib to Treat Newly Diagnosed Ph+ CML
Bosulif is now indicated for adults with newly diagnosed chronic phase, Philadelphia chromosome–positive ...
DECEMBER 30, 2017
FDA Approves Alecensa for NSCLC
The FDA approved a new indication for Genentech's Alecensa, to treat people with anaplastic lymphoma kinase ...
NOVEMBER 7, 2017
Besponsa Approved for Adults With Relapsed/Refractory ALL
The FDA has approved inotuzumab ozogamicin (Besponsa, Pfizer) for the treatment of adults with relapsed or ...
AUGUST 22, 2017
